|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis.
|
30638930 |
2019 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE<sup>-/-</sup> Mice Fed with a High-Fat Diet.
|
28491104 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both SREBP-2 and SCAP are candidates to contribute to the development of atherosclerosis.
|
16466730 |
2006 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
SCAP knockdown in vascular smooth muscle cells alleviates atherosclerosis plaque formation via up-regulating autophagy in ApoE<sup>-/-</sup> mice.
|
30462530 |
2019 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE<sup>-/-</sup> Mice Fed with a High-Fat Diet.
|
28491104 |
2017 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
SCAP knockdown in vascular smooth muscle cells alleviates atherosclerosis plaque formation via up-regulating autophagy in ApoE<sup>-/-</sup> mice.
|
30462530 |
2019 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both SREBP-2 and SCAP are candidates to contribute to the development of atherosclerosis.
|
16466730 |
2006 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Targeting SCAP N-glycosylation may provide a promising means of treating malignancies and metabolic diseases.
|
26555173 |
2015 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
What's more, downregulation of SCAP could weaken the cancer-promoting effects of estrogen on BC.
|
31360104 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study reveals a previously unrecognized negative feedback loop in SCAP/SREBP-1 signaling mediated by miR-29 and suggests that miR-29 treatment may represent an effective means to target GBM.
|
27477273 |
2016 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Xenograft studies reveal that blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth.
|
26555173 |
2015 |
|
Metabolic Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Increased hepatic INSIG-SCAP-SREBP expression is associated with cholesterol metabolism disorder in assisted reproductive technology-conceived aged mice.
|
30562550 |
2019 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Targeting SCAP N-glycosylation may provide a promising means of treating malignancies and metabolic diseases.
|
26555173 |
2015 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
We explored the association between the variants of the sterol-regulatory element-binding transcription factor-1 (SREBF1) gene and the SREBP cleavage-activation protein (SCAP) gene with AAP-induced MetS in a genetic case-control study.
|
26982812 |
2016 |
|
Metabolic Syndrome X
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.
|
27885915 |
2016 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Xenograft studies reveal that blocking SCAP N-glycosylation ameliorates EGFRvIII-driven glioblastoma growth.
|
26555173 |
2015 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study reveals a previously unrecognized negative feedback loop in SCAP/SREBP-1 signaling mediated by miR-29 and suggests that miR-29 treatment may represent an effective means to target GBM.
|
27477273 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, Targeting SCAP may provide a promising means of treating BC and a new perspective for the tumorigenesis of bladder cancer.
|
31360104 |
2019 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, Targeting SCAP may provide a promising means of treating BC and a new perspective for the tumorigenesis of bladder cancer.
|
31360104 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, targeting of SREBP-2 with Fatostatin which specifically inhibits SCAP (SREBP cleavage-activating protein) and prevents SREBP activation, attenuated breast cancer-induced osteolysis in vivo.
|
30394316 |
2019 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study to investigate whether the common variants of genes from the SREBP2 activating-related pathway, involving SREBP2, SCAP, INSIG1 and INSIG2 genes, were associated with coronary heart disease (CHD) of Chinese Han population individually or interactively.
|
19740467 |
2010 |
|
Cytomegalovirus Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our data demonstrate that the induction of PERK during HCMV infection is necessary for full activation of lipogenesis; this effect appears to be mediated by limiting the levels of Insig1 thus freeing SREBP1-SCAP complexes for SREBP1 processing.
|
23592989 |
2013 |
|
Dental Pulp Necrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Apical papilla represents a source of an enriched mesenchymal stem cell (MSC) population (stem cells of the apical papilla [SCAPs]) that modulates root development and may participate in regenerative endodontic procedures in immature teeth with pulp necrosis.
|
28190588 |
2017 |
|
Hypertensive disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A case-control study on 702 high blood pressure (HBP) children and 1319 controls was conducted to explore the correlation between single nucleotide polymorphism markers (rs12487736 and rs12490383) of SCAP and BP phenotypes.
|
28542467 |
2017 |
|
Intestinal Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
After 4 days of tamoxifen, Vil-Scap(-) mice succumb with a severe enteropathy and near-complete collapse of intestinal mucosa.
|
25896350 |
2015 |